July 24, 2023 03:48 PM EDT
Pharma
Law

Ex­elix­is, Te­va reach set­tle­ment on Cabome­tyx patent dis­pute

Paul Schloesser

Associate Editor

Ex­elix­is has set­tled a patent dis­pute over Te­va’s at­tempt to mar­ket a gener­ic ver­sion of its block­buster can­cer drug Cabome­tyx, push­ing gener­ic com­pe­ti­tion in­to the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times